These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16408127)

  • 21. Fibrosis and matrix metalloproteinases in rat renal allografts.
    Inkinen KA; Soots AP; Krogerus LA; Lautenschlager IT; Ahonen JP
    Transpl Int; 2005 May; 18(5):506-12. PubMed ID: 15819797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines.
    Hofmann A; Laue S; Rost AK; Scherbaum WA; Aust G
    Thyroid; 1998 Mar; 8(3):203-14. PubMed ID: 9545106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered gene expression levels of matrix metalloproteinases and their inhibitors in periodontitis-affected gingival tissue.
    Kubota T; Itagaki M; Hoshino C; Nagata M; Morozumi T; Kobayashi T; Takagi R; Yoshie H
    J Periodontol; 2008 Jan; 79(1):166-73. PubMed ID: 18166107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and localization of matrix metalloproteinases (MT1-MMP, MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) during synepitheliochorial placentation of goats (Capra hircus).
    Uekita T; Yamanouchi K; Sato H; Tojo H; Seiki M; Tachi C
    Placenta; 2004 Nov; 25(10):810-9. PubMed ID: 15451196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients.
    Galboiz Y; Shapiro S; Lahat N; Rawashdeh H; Miller A
    Ann Neurol; 2001 Oct; 50(4):443-51. PubMed ID: 11601495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PAF-induced furin and MT1-MMP expression is independent of MMP-2 activation in corneal myofibroblasts.
    Ottino P; He J; Axelrad TW; Bazan HE
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):487-96. PubMed ID: 15671273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of chronic allograft nephropathy with vitamin D.
    Hullett DA; Laeseke PF; Malin G; Nessel R; Sollinger HW; Becker BN
    Transpl Int; 2005 Oct; 18(10):1175-86. PubMed ID: 16162105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
    Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
    J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of matrix gelatinases and metalloproteinase-activating process in acute kidney rejection.
    Laplante A; Liu D; Demeule M; Annabi B; Murphy GF; Daloze P; Chen H; Béliveau R
    Transpl Int; 2003 Apr; 16(4):262-9. PubMed ID: 12730807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Influence of recombinant transforming growth factor-beta3 on collagen synthesis and deposition: experiment with rat cell model of liver fibrosis].
    Li Q; Zhou X; Yu J; Qian W; Xu KS
    Zhonghua Yi Xue Za Zhi; 2008 May; 88(18):1273-8. PubMed ID: 18844103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matrix metalloproteinase expression in rat pancreatic islets.
    Barro C; Zaoui P; Morel F; Benhamou PY
    Pancreas; 1998 Nov; 17(4):378-82. PubMed ID: 9821179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.
    Truter SL; Catanzaro DF; Supino PG; Gupta A; Carter J; Herrold EM; Dumlao TF; Borer JS
    Cardiology; 2009; 113(3):161-8. PubMed ID: 19129699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of TGF-beta1, extracellular matrix, and matrix metalloproteinase in the healing process of the pancreas after induction of acute necrotizing pancreatitis using arginine in rats.
    Kihara Y; Tashiro M; Nakamura H; Yamaguchi T; Yoshikawa H; Otsuki M
    Pancreas; 2001 Oct; 23(3):288-95. PubMed ID: 11590325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat.
    Szabo A; Lutz J; Schleimer K; Antus B; Hamar P; Philipp T; Heemann U
    Kidney Int; 2000 Mar; 57(3):982-91. PubMed ID: 10720951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis.
    Rodgers KD; Rao V; Meehan DT; Fager N; Gotwals P; Ryan ST; Koteliansky V; Nemori R; Cosgrove D
    Kidney Int; 2003 Apr; 63(4):1338-55. PubMed ID: 12631350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
    Ries C; Loher F; Zang C; Ismair MG; Petrides PE
    Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats.
    Lutz J; Yao Y; Song E; Antus B; Hamar P; Liu S; Heemann U
    Transplantation; 2005 Mar; 79(6):655-61. PubMed ID: 15785371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
    Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts.
    Pan F; Ebbs A; Wynn C; Erickson L; Jang MS; Crews G; Fisniku O; Kobayashi M; Paul LC; Benediktsson H; Jiang AH
    Transplantation; 2003 Apr; 75(8):1110-4. PubMed ID: 12717186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.